Ascendis Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Ascendis Pharma AS
ASND Stock  USD 213.29  0.05  0.02%   
Ascendis Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ascendis Pharma's valuation are provided below:
Gross Profit
561.2 M
Profit Margin
(0.36)
Market Capitalization
13 B
Enterprise Value Revenue
17.58
Revenue
646.5 M
There are over one hundred nineteen available fundamental signals for Ascendis Pharma AS, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Ascendis Pharma's prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 7.3 B. The current year's Enterprise Value is expected to grow to about 7.6 B

Ascendis Pharma Total Revenue

439.1 Million

Check Ascendis Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascendis Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 21.4 M, Interest Expense of 79.1 M or Selling General Administrative of 343.6 M, as well as many indicators such as Price To Sales Ratio of 18.1, Dividend Yield of 0.0 or Days Sales Outstanding of 158. Ascendis financial statements analysis is a perfect complement when working with Ascendis Pharma Valuation or Volatility modules.
  
Build AI portfolio with Ascendis Stock
Check out the analysis of Ascendis Pharma Correlation against competitors.

Ascendis Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.4 B1.4 B566.2 M
Slightly volatile
Total Current Liabilities1.1 B1 B287.8 M
Slightly volatile
Property Plant And Equipment Net119.2 M113.5 M51.2 M
Slightly volatile
Current Deferred Revenue800.3 K842.4 K6.6 M
Slightly volatile
Accounts Payable116.4 M110.9 M41.3 M
Slightly volatile
Cash675.6 M643.5 M307.8 M
Slightly volatile
Non Current Assets Total83.1 M136.4 M75.4 M
Slightly volatile
Non Currrent Assets Other2.8 M2.7 M1.1 M
Slightly volatile
Cash And Short Term Investments358.8 M643.5 M328.5 M
Slightly volatile
Net Receivables200.8 M191.2 M36.7 M
Slightly volatile
Good Will2.8 M3.1 M3.4 M
Slightly volatile
Common Stock Total Equity4.2 M8.3 M4.8 M
Slightly volatile
Liabilities And Stockholders Equity1.4 B1.4 B566.2 M
Slightly volatile
Non Current Liabilities Total455.6 M433.9 M115.5 M
Slightly volatile
Other Current Assets47.6 M45.3 M20.6 M
Slightly volatile
Total Liabilities1.6 B1.5 B395.6 M
Slightly volatile
Property Plant And Equipment Gross221.4 M210.9 M76.8 M
Slightly volatile
Total Current Assets1.3 B1.2 B487.3 M
Slightly volatile
Accumulated Other Comprehensive Income1.9 M2.1 M19 M
Very volatile
Common Stock5.5 M9.4 M5.1 M
Slightly volatile
Other Current Liabilities383.7 M365.4 M92.1 M
Slightly volatile
Common Stock Shares Outstanding41.1 M66.6 M36.2 M
Slightly volatile
Other Stockholder Equity3 B2.8 B1.1 B
Slightly volatile
Net Tangible Assets374.1 M297.3 M270.4 M
Slightly volatile
Other Assets2.3 M2.2 M1 M
Slightly volatile
Property Plant Equipment155.9 M148.5 M58.4 M
Slightly volatile
Intangible Assets455.7 K479.7 K17.8 B
Pretty Stable
Net Invested Capital647.5 M863.5 M443 M
Slightly volatile
Net Working Capital167.2 M175.9 M318.3 M
Slightly volatile
Capital Stock7.9 M9.4 M6.7 M
Slightly volatile

Ascendis Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization21.4 M20.4 M7.8 M
Slightly volatile
Interest Expense79.1 M75.3 M17.8 M
Slightly volatile
Selling General Administrative343.6 M327.2 M105.4 M
Slightly volatile
Total Revenue439.1 M418.2 M98.4 M
Slightly volatile
Gross Profit385.7 M367.3 M86.1 M
Slightly volatile
Other Operating Expenses775.7 M738.8 M295.2 M
Slightly volatile
Research Development189.4 M353.1 M164.9 M
Slightly volatile
Total Operating Expenses722.3 M687.9 M282.9 M
Slightly volatile
Interest Income17.3 M16.5 M8.2 M
Slightly volatile
Reconciled Depreciation12.1 M20.4 M7.4 M
Slightly volatile
Selling And Marketing Expenses4.5 M5.1 M5.5 M
Slightly volatile

Ascendis Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation115.3 M109.8 M38.2 M
Slightly volatile
Begin Period Cash Flow282.5 M451 M241.4 M
Slightly volatile
Depreciation21.4 M20.4 M7.8 M
Slightly volatile
Capital Expenditures1.6 M1.6 M4.7 M
Slightly volatile
End Period Cash Flow328.5 M643.5 M287.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio18.119.05213
Pretty Stable
Days Sales Outstanding15815078.5897
Pretty Stable
Stock Based Compensation To Revenue0.220.241.8482
Pretty Stable
Capex To Depreciation0.0880.09261.1046
Slightly volatile
EV To Sales18.7919.78192
Pretty Stable
Inventory Turnover0.10.130.0733
Slightly volatile
Days Of Inventory On Hand4.4 K2.8 K6.4 K
Slightly volatile
Payables Turnover0.220.410.1406
Slightly volatile
Sales General And Administrative To Revenue0.670.72.0778
Pretty Stable
Research And Ddevelopement To Revenue0.720.7611.9459
Very volatile
Capex To Revenue0.00340.00350.4816
Pretty Stable
Cash Per Share6.158.76.909
Slightly volatile
Days Payables Outstanding8699144.7 K
Slightly volatile
Intangibles To Total Assets0.00370.00390.0437
Slightly volatile
Current Ratio1.01.055.2161
Very volatile
Receivables Turnover2.392.51111
Very volatile
Capex Per Share0.02110.02220.1015
Pretty Stable
Revenue Per Share5.945.651.8795
Slightly volatile
Interest Debt Per Share15.0514.344.5593
Slightly volatile
Debt To Assets0.690.650.2496
Slightly volatile
Graham Number1.142.01.8642
Slightly volatile
Operating Cycle2.5 K2.3 K1.3 K
Slightly volatile
Days Of Payables Outstanding8699144.7 K
Slightly volatile
Ebt Per Ebit0.781.210.9696
Slightly volatile
Long Term Debt To Capitalization0.931.270.468
Slightly volatile
Total Debt To Capitalization1.081.030.4279
Slightly volatile
Quick Ratio0.720.765.0919
Very volatile
Net Income Per E B T0.780.910.9656
Pretty Stable
Cash Ratio0.670.714.5415
Very volatile
Cash Conversion Cycle1.7 K1.6 K559
Slightly volatile
Days Of Inventory Outstanding4.4 K2.8 K6.4 K
Slightly volatile
Days Of Sales Outstanding15815078.5897
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.141.161.1024
Slightly volatile
Fixed Asset Turnover3.924.244.7558
Slightly volatile
Debt Ratio0.690.650.2496
Slightly volatile
Price Sales Ratio18.119.05213
Pretty Stable
Asset Turnover0.210.350.2495
Slightly volatile
Gross Profit Margin0.610.790.6141
Slightly volatile

Ascendis Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap7.3 B6.9 B3.5 B
Slightly volatile
Enterprise Value7.6 B7.2 B3.4 B
Slightly volatile

Ascendis Fundamental Market Drivers

Forward Price Earnings50
Cash And Short Term Investments559.5 M

Ascendis Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ascendis Pharma Financial Statements

Ascendis Pharma stakeholders use historical fundamental indicators, such as Ascendis Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ascendis Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascendis Pharma's assets and liabilities are reflected in the revenues and expenses on Ascendis Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascendis Pharma AS. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue842.4 K800.3 K
Total Revenue418.2 M439.1 M
Cost Of Revenue39.8 M37.8 M
Stock Based Compensation To Revenue 0.24  0.22 
Sales General And Administrative To Revenue 0.70  0.67 
Research And Ddevelopement To Revenue 0.76  0.72 
Revenue Per Share 5.65  5.94 
Ebit Per Revenue(0.88)(0.93)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:
How To Invest In Ascendis
Details
Is Ascendis Stock a good investment?
Details
What is Ascendis Pharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ascendis Pharma Correlation against competitors.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.48)
Revenue Per Share
10.729
Quarterly Revenue Growth
2.694
Return On Assets
(0.08)
Return On Equity
(8.18)
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY